Clinical Trial Update: Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Abivertinib Maleate to Gefitinib in advanced non-small cell lung cancer with sensitive EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abivertinib Maleate (abivertinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Conditions: Advanced Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN